101
|
Jeakal E, Park K, Lee E, Strauss GP, Choi KH. Validation of the Brief Negative Symptom Scale in Korean patients with schizophrenia. Asia Pac Psychiatry 2020; 12:e12382. [PMID: 31960582 DOI: 10.1111/appy.12382] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Revised: 11/21/2019] [Accepted: 01/02/2020] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The Brief Negative Symptom Scale (BNSS) was developed based on the current consensus on negative symptoms. We validated the Korean version of the BNSS (K-BNSS) and explored the factor structure of negative symptoms among 173 Koreans with schizophrenia. METHODS Clinical interviews and neurocognitive assessments were administered to evaluate the factor structure, validity, and reliability of the K-BNSS. RESULTS The five-factor model of the K-BNSS showed excellent reliability and validity. DISCUSSION Our findings confirm that the K-BNSS is a promising instrument for assessing negative symptoms of schizophrenia, and that negative symptoms are best conceptualized in the form of five domains.
Collapse
|
102
|
Mun GA, Moldakhan I, Serikbay AM, Kaldybekov D, Suleimenov IE, Park K. Hydrophilic interpolymer associates – the key to solving the problem of pre-biological evolution. INTERNATIONAL JOURNAL OF BIOLOGY AND CHEMISTRY 2020. [DOI: 10.26577/ijbch.2020.v13.i1.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
103
|
Larin I, Zhang Y, Gasparian A, Gan L, Miskimen R, Khandaker M, Dale D, Danagoulian S, Pasyuk E, Gao H, Ahmidouch A, Ambrozewicz P, Baturin V, Burkert V, Clinton E, Deur A, Dolgolenko A, Dutta D, Fedotov G, Feng J, Gevorkyan S, Glamazdin A, Guo L, Isupov E, Ito MM, Klein F, Kowalski S, Kubarovsky A, Kubarovsky V, Lawrence D, Lu H, Ma L, Matveev V, Morrison B, Micherdzinska A, Nakagawa I, Park K, Pedroni R, Phelps W, Protopopescu D, Rimal D, Romanov D, Salgado C, Shahinyan A, Sober D, Stepanyan S, Tarasov VV, Taylor S, Vasiliev A, Wood M, Ye L, Zihlmann B. Precision measurement of the neutral pion lifetime. Science 2020; 368:506-509. [PMID: 32355026 DOI: 10.1126/science.aay6641] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 03/30/2020] [Indexed: 11/02/2022]
Abstract
The explicit breaking of the axial symmetry by quantum fluctuations gives rise to the so-called axial anomaly. This phenomenon is solely responsible for the decay of the neutral pion π0 into two photons (γγ), leading to its unusually short lifetime. We precisely measured the decay width Γ of the [Formula: see text] process. The differential cross sections for π0 photoproduction at forward angles were measured on two targets, carbon-12 and silicon-28, yielding [Formula: see text], where stat. denotes the statistical uncertainty and syst. the systematic uncertainty. We combined the results of this and an earlier experiment to generate a weighted average of [Formula: see text] Our final result has a total uncertainty of 1.50% and confirms the prediction based on the chiral anomaly in quantum chromodynamics.
Collapse
|
104
|
Park K, Ko B, Kim D. P274 Electrode number constrained transcranial direct current stimulation optimization strategy. Clin Neurophysiol 2020. [DOI: 10.1016/j.clinph.2019.12.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
105
|
Park K, Kim DY, Jang YH, Kim MG, Yang DR, Hong S. Comprehensive analysis of a hybrid FO/crystallization/RO process for improving its economic feasibility to seawater desalination. WATER RESEARCH 2020; 171:115426. [PMID: 31887548 DOI: 10.1016/j.watres.2019.115426] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Revised: 11/28/2019] [Accepted: 12/19/2019] [Indexed: 06/10/2023]
Abstract
In this study, the FO/crystallization/RO hybrid process was analyzed comprehensively, including experimentation, modeling, and energy and cost estimation, to examine and improve its feasibility to seawater desalination. A new operating strategy by heating the FO process to 45 °C was suggested, and a detailed process design was conducted. A comparative analysis with the conventional seawater reverse osmosis (SWRO) process was performed in terms of specific energy consumption (SEC) and specific water cost (SWC). The hybrid process can produce fresh water with SWC of 0.6964 $/m3, electrical SEC of 2.71 kWh/m3, and thermal SEC of 14.684 kWh/m3. Compared to the conventional SWRO process (SWC of 0.6890 $/m3 and electrical SEC of 2.674 kWh/m3), the hybrid process can produce water with comparable cost and energy consumption. An economic feasibility study that utilized the waste heat and the developed FO technology was also carried out to investigate future developments of the hybrid process. The SWC can be reduced to 0.6435 $/m3 with free waste heat energy. The permeate water quality of the hybrid process was about half that of the conventional SWRO process on molar basis. The results revealed that the FO/crystallization/RO hybrid process can be utilized as a competitive process for seawater desalination with high recovery and high water quality.
Collapse
|
106
|
Kim C, Kim D, Hong H, Park K. Thermoelectric properties of La3+ and Ce3+ co-doped CaMnO3 prepared by tape casting. Ann Ital Chir 2020. [DOI: 10.1016/j.jeurceramsoc.2019.08.021] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
107
|
Kim R, Do Y, Park K, Park H, Kim D, Heo S. Abstract No. 682 Updates for extremity arteriovenous malformations involving the bone: approach for embolization and its therapeutic outcomes. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
108
|
Zhan M, Gwak G, Kim DI, Park K, Hong S. Quantitative analysis of the irreversible membrane fouling of forward osmosis during wastewater reclamation: Correlation with the modified fouling index. J Memb Sci 2020. [DOI: 10.1016/j.memsci.2019.117757] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
109
|
Park K, Kim J, Yang DR, Hong S. Towards a low-energy seawater reverse osmosis desalination plant: A review and theoretical analysis for future directions. J Memb Sci 2020. [DOI: 10.1016/j.memsci.2019.117607] [Citation(s) in RCA: 71] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
110
|
Park K, Jaekal E, Yoon S, Lee SH, Choi KH. Diagnostic Utility and Psychometric Properties of the Beck Depression Inventory-II Among Korean Adults. Front Psychol 2020; 10:2934. [PMID: 32038360 PMCID: PMC6985267 DOI: 10.3389/fpsyg.2019.02934] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Accepted: 12/11/2019] [Indexed: 11/29/2022] Open
Abstract
The Beck Depression Inventory-II (BDI-II) is one of the most widely used depression assessment tools in Korea. However, the psychometric properties and diagnostic cut-off point of the official Korean version of the BDI-II have not yet been reported. This study aims to clarify the psychometric properties and diagnostic utility of the Korean BDI-II. A total of 1,145 clinical and non-clinical Korean adults participated in this study. The BDI-II showed a high level of internal consistency and high correlations with other depression-related measures. Confirmatory factor analysis (CFA) was performed, and a 3-factor model showed the best model fit. To identify the diagnostic utility of the BDI-II, the Quality Assessment of Diagnostic Accuracy Studies 2nd Edition (QUADAS-2) methodology was applied in participant recruitment and research design. Results of ROC curve analysis suggested two optimal cut-off scores, 23 points for detecting major depressive disorder (MDD) (83.3% sensitivity, 86.8% specificity) and 17 points for depressive-related disorder (80.9% sensitivity, 76.4% specificity). To identify the usefulness of the BDI-II as a severity assessment tool or screening tool, a test information curve (TIC) was generated with an Item Response Theory (IRT) analysis. The TIC was flat and plateau-like, indicating its appropriateness as a severity rating tool. Research data supports the BDI-II as a reliable and valid screening tool as well as a severity rating tool in the Korean adult population.
Collapse
|
111
|
Jin Y, Park K, Yang DR. Modified kinetic rate equation model for cooling crystallization. KOREAN J CHEM ENG 2019. [DOI: 10.1007/s11814-019-0415-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
112
|
Cho Y, Kim J, Elabd A, Choi S, Park K, Kwon TW, Lee J, Char K, Coskun A, Choi JW. A Pyrene-Poly(acrylic acid)-Polyrotaxane Supramolecular Binder Network for High-Performance Silicon Negative Electrodes. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2019; 31:e1905048. [PMID: 31693231 DOI: 10.1002/adma.201905048] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 10/06/2019] [Indexed: 06/10/2023]
Abstract
Although being incorporated in commercial lithium-ion batteries for a while, the weight portion of silicon monoxide (SiOx , x ≈ 1) is only less than 10 wt% due to the insufficient cycle life. Along this line, polymeric binders that can assist in maintaining the mechanical integrity and interfacial stability of SiOx electrodes are desired to realize higher contents of SiOx . Herein, a pyrene-poly(acrylic acid) (PAA)-polyrotaxane (PR) supramolecular network is reported as a polymeric binder for SiOx with 100 wt%. The noncovalent functionalization of a carbon coating layer on the SiOx is achieved by using a hydroxylated pyrene derivative via the π-π stacking interaction, which simultaneously enables hydrogen bonding interactions with the PR-PAA network through its hydroxyl moiety. Moreover, the PR's ring sliding while being crosslinked to PAA endows a high elasticity to the entire polymer network, effectively buffering the volume expansion of SiOx and largely mitigating the electrode swelling. Based on these extraordinary physicochemical properties of the pyrene-PAA-PR supramolecular binder, the robust cycling of SiOx electrodes is demonstrated at commercial levels of areal loading in both half-cell and full-cell configurations.
Collapse
|
113
|
Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Ann Oncol 2019; 29:1548-1553. [PMID: 29767677 DOI: 10.1093/annonc/mdy177] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an antitumor immune response. This phase III trial determined the efficacy of bavituximab combined with docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). Patients and methods Key eligibility criteria included advanced non-squamous NSCLC with disease progression after treatment with platinum-based doublet chemotherapy, evidence of disease control after at least two cycles of first-line therapy, presence of measurable disease, ECOG performance status 0 or 1, adequate bone marrow and organ function, and no recent history of clinically significant bleeding. Eligible patients were randomized 1 : 1 to receive up to six 21-day cycles of docetaxel plus either weekly bavituximab 3 mg/kg or placebo until progression or toxicity. The primary end point was overall survival (OS). Results A total of 597 patients were enrolled. Median OS was 10.5 months in the docetaxel + bavituximab arm and was 10.9 months in the docetaxel + placebo arm (HR 1.06; 95% CI 0.88-1.29; P = 0.533). There was no difference in progression-free survival (HR 1.00; 95% CI 0.82-1.22; P = 0.990). Toxicities were manageable and similar between arms. In subset analysis, among patients with high baseline serum β2GP1 levels ≥200 µg/ml, a nonsignificant OS trend favored the bavituximab arm (HR 0.82; 95% CI 0.63-1.06; P = 0.134). Among patients who received post-study immune checkpoint inhibitor therapy, OS favored the bavituximab arm (HR 0.46; 95% CI 0.26-0.81; P = 0.006). Conclusions The combination of bavituximab plus docetaxel is not superior to docetaxel in patients with previously treated advanced NSCLC. The addition of bavituximab to docetaxel does not meaningfully increase toxicity. The potential benefit of bavituximab observed in patients with high β2GP1 levels and in patients subsequently treated with immune checkpoint inhibitors requires further investigation. Clinical trial number NCT01999673.
Collapse
|
114
|
Gottfried M, de Marinis F, Tu H, Laktionov K, Feng J, Poltoratskiy A, Zhao J, Tan EH, Lee V, Kowalski D, Yang CT, Srinivasa B, Passaro A, Clementi L, Tang W, Huang DL, Cseh A, Park K, Zhou C, Wu YL. Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
115
|
Park K, Zhou J, Kim DW, Ahmad A, Soo R, Bruns R, Straub J, Johne A, Scheele J, Yang JH, Wu YL. Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
116
|
Park K, Felip E, Veillon R, Cortot A, Mazieres J, Sakai H, Reinmuth N, Viteri S, Chen YM, Han JY, Jang TW, Morise M, Sakamoto T, Tokito T, Cho B, Bruns R, Scheele J, Straub J, Le X, Paik P. Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz420.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
117
|
Oh S, Kim JJ, Oh SY, Park K. Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz434.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
118
|
Passaro A, De Marinis F, Tu H, Laktionov K, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa B, Clementi L, Tang W, Huang DL, Cseh A, Park K, Zhou C, Wu YL. Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
119
|
Ryoo H, Park K, Kim J. DEVELOPMENT OF MINI-COMPREHENSIVE GERIATRIC ASSESSMENT FOR THE ELDERLY CANCER PATIENTS BASED ON RELATIONSHIPS BETWEEN COMPREHENSIVE GERIATRIC ASSESSMENT ITEMS AND PERFORMANCE STATUS. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31243-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
120
|
Kim SB, Keam B, Shin S, Chae Y, Kim T, Kim MS, Kim J, Park K, Ahn J, Park L, Lee E, Juhn J, Kim S, Hong SB, Ahn MJ. First in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
121
|
Seong M, Park S, Jung H, Sun J, Lee S, Ahn J, Park K, Kim S, Ahn M. P1.01-97 Modified RANO-LM Criteria to Evaluate the Radiological Response of Osimertinib in EGFR T790M Positive NSCLC with Leptomeningeal Metastases. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
122
|
Jung H, Hong S, Park J, Park M, Sun J, Lee S, Ahn J, Ahn M, Park K. MA19.06 Successful Development of Realtime Automatically Updated Data Warehouse in Health Care (ROOT-S). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.659] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
123
|
Park K. P2.13-13 Should Visceral Pleural Invasion Be Prognostic Factor in Patient with Smaller Sized Adenocarcinoma? J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
124
|
Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, Tan S, Loong H, Bauer T, Kim Y, Horiike A, Park K, Shah M, McCoach C, Bazhenova L, Seto T, Brose M, Pennell N, Weiss J, Matos I, Peled N, Cho B, Ohe Y, Reckamp K, Boni V, Satouchi M, Falchook G, Akerley W, Daga H, Sakamoto T, Patel J, Lakhani N, Barlesi F, Burkard M, Zhu V, Moreno Garcia V, Medioni J, Matrana M, Rolfo C, Lee D, Nechushtan H, Johnson M, Velcheti V, Nishio M, Toyozawa R, Ohashi K, Song L, Han J, Spira A, De Braud F, Staal Rohrberg K, Takeuchi S, Sakakibara J, Waqar S, Kenmotsu H, Wilson F, B.Nair, Olek E, Kherani J, Ebata K, Zhu E, Nguyen M, Yang L, Huang X, Cruickshank S, Rothenberg S, Solomon B, Goto K, Subbiah V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.059] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
125
|
Ku B, Jung H, Sun J, Lee S, Ahn J, Park K, Ahn M. P2.14-61 Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|